HAE Junior is a patient organisation seeking to improve the quality of life of children & young people
suffering from hereditary angioedema (HAE). HAE is a rare and potentially life-threatening immune
disorder, causing recurring painful swellings on various parts of the body.
The organisation was established in Prague, in December 2019, by a group of parents of HAE pediatric
patients.
HAE Junior’s main goals are:
1. ADVOCATE for better access to modern HAE medicine, therapies and care.
2. INFORM & ADVISE in relation to HAE diagnose.
3. FOSTER patient networking (inter)nationally.
4. SUPPORT INCLUSION of HAE kids & youth.
Here is a list of conditions this partner raises awareness and advocacy for:
Clinical stage pharmaceutical company KalVista Pharmaceuticals (“KalVista”) saw positive data from a Phase 2 clinical trial evaluating its experimental therapy KVD900, shared MedCity News. The
After in-licensing Icatibant, a Bradykinin B2 receptor agonist, from Slayback Pharma, global pharmaceutical and biosimilar leader Sandoz is launching a generic version in the
In a press release from late November, pharmaceutical company BioCryst Pharmaceuticals, Inc. (“BioCryst”) announced the publication of data from its APeX-J clinical trial in Allergy.
HAE Junior is a Czech-based patient organization aiming to improve the quality of life of children & youth with hereditary angioedema (HAE). It was set
According to an article from Biospace, Takeda Pharmaceuticals has released the results from their Phase 3 HELP trial, an extension study of TAKHZYRO. This hereditary
From November 13th through the 15th, the American College of Allergy, Asthma & Immunology (ACAAI) held their 2020 Annual Scientific Meeting. While the coronavirus pandemic
© Copyright Patient Worthy
